On January 23, 2026 (before the trading session), the Company, the vendor ZTan Limited, and the placing agent entered into a placing and subscription agreement. Pursuant to this agreement, (i) the vendor has agreed to sell, and the placing agent has agreed to act as the vendor's agent to use its best efforts to procure no fewer than six placees to subscribe for the Placing Shares at the placing price of HK$5.60 per share, and (ii) the vendor has conditionally agreed to subscribe, and the Company has conditionally agreed to allot and issue to the vendor the Top-up Subscription Shares (the number of which shall be equal to the number of Placing Shares actually placed by the placing agent under the agreement, namely 92 million shares) at a top-up subscription price of HK$5.60 per share, equivalent to the placing price, under the general mandate. The Placing Shares represent approximately 7.27% of the Company's existing issued share capital as of the date of this announcement, and approximately 6.77% of the Company's issued share capital as enlarged by the allotment and issue of the Top-up Subscription Shares immediately following the completion of the Top-up Subscription (assuming no change in the issued share capital of the Company from the date of this announcement up to the completion of the Top-up Subscription other than the allotment and issue of the Top-up Subscription Shares). The placing price is HK$5.60 per Placing Share, representing a discount of approximately 12.09% to the closing price of HK$6.37 per share as quoted on the Stock Exchange on the last trading day. Upon completion, the gross proceeds from the Top-up Subscription are expected to be approximately HK$515 million. After deducting all related fees, costs, and expenses incidental to the Placing and the Top-up Subscription (including, but not limited to, legal fees and expenses), the net proceeds from the Top-up Subscription are estimated to be approximately HK$501 million. After deducting these fees, costs, and expenses, the estimated net top-up subscription price is approximately HK$5.44 per Top-up Subscription Share. The Company intends to allocate the net proceeds from the Top-up Subscription for the following purposes: (i) approximately 50% will be used to fund R&D initiatives, including, but not limited to, the development of non-invasive brain-computer interface (BCI) intervention systems, multimodal deep reasoning large models, a consumer-facing extended digital health platform, the integration of medical large models with home appliances, and supporting large-scale clinical trials for key therapeutic pipelines; these funds are expected to be fully utilized by September 30, 2027. Approximately 30% will be allocated to domestic and international market development, covering costs associated with establishing national branch offices, supporting academic conferences and large-scale validation projects in the domestic medical market, and investing in the setup of regional subsidiaries to serve local markets; these funds are expected to be fully utilized by June 30, 2027. Approximately 10% will be used for strategic investments and acquisitions, primarily aimed at investing in or acquiring upstream and downstream companies within the digital health ecosystem (such as smart hardware manufacturers) to enhance the Company's integrated product and service offerings; these funds are expected to be fully utilized by June 30, 2027. And (iv) approximately 10% will be used to supplement the working capital of the Company and its subsidiaries for general corporate purposes; these funds are expected to be fully utilized by December 31, 2026.